Advertisement
Canada markets closed

  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     

  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • CAD/USD

    0.7233
    -0.0020 (-0.27%)
     

  • CRUDE OIL

    85.36
    0.00 (0.00%)
     

  • Bitcoin CAD

    88,112.38
    +1,286.07 (+1.48%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,400.80
    -7.00 (-0.29%)
     

  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • NASDAQ futures

    17,903.25
    +22.00 (+0.12%)
     

  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6810
    -0.0014 (-0.21%)
     
BREAKING:

$535B CANADA BUDGET PROJECTS $39.8B DEFICIT, AIMS TO RESTORE ECONOMIC FAIRNESS

It seeks to ease the housing and affordability crisis by making older, wealthier Canadians pay more

Five Star Equities Issues New Research Reports on FEYE, HZNP, INO and OWW

ACCESSWIRE

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

FireEye Inc. (NASDAQ:FEYE - News) shares declined 8.04 percent to close at $71.50 a share Wednesday. The stock traded between $71.49 and $77.25 on volume of 8.02 million shares traded. The company’s lock-up expiration saw 14.0 million shares become available for sale on the open market. Shares of FireEye are up approximately 63.0 percent year-to-date.

Get more information on FireEye and free access to the in-depth equity report at:
www.FiveStarEquities.com/FEYE

Horizon Pharma Inc. (NASDAQ:HZNP - News) shares jumped 9.13 percent to close at $16.02 a share Wednesday. The stock traded between $15.40 and $18.30 on volume 14.96 million shares traded. The company announced that it has acquired Vidara Therapeutics International Ltd. for $660.0 million. Shares of Horizon Pharma are up approximately 110.0 percent year-to-date.

ADVERTISEMENT

Get more information on Horizon Pharma and free access to the in-depth equity report at:
www.FiveStarEquities.com/HZNP

Inovio Pharmaceuticals Inc. (NYSEMKT:INO - News) shares 11.37 percent to close at $3.82 a share Wednesday. The stock traded between $3.43 and $3.85 on volume 14.34 million shares traded. The company reported total revenue was $1.7 million for the fourth quarter of 2013, up from $1.1 million a year ago. Shares of Inovio Pharmaceuticals are up approximately 30.0 percent year-to-date.

Get more information on Inovio Pharmaceuticals free access to the in-depth equity report at:
www.FiveStarEquities.com/INO

Orbitz Worldwide, Inc. (NYSE:OWW - News) shares dropped 9.16 percent to close at $8.13 a share Wednesday. The stock traded between $8.08 and $8.54 on volume of 2.13 million shares traded. Analysts at Goldman Sachs have recently downgraded the company’s rating to “sell” from “neutral”. Shares of Orbitz Worldwide are up approximately 13.0 percent year-to-date.

Get more information on Orbitz Worldwide and free access to the in-depth equity report at:
www.FiveStarEquities.com/OWW

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com